CorMedix Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
9,133.10
20,453.40
18,187.50
24,643.60
33,009.90
26,829.60
Depreciation, Depletion & Amortization
5.20
15.10
15.10
25.60
36.90
74.20
Other Funds
-
6,723.20
26.50
-
-
1,110.60
Funds from Operations
3,560.50
6,543.10
13,125.60
23,152.90
31,463.80
25,644.80
Changes in Working Capital
162.60
1.70
770.20
887.50
2,876.60
1,944.20
Net Operating Cash Flow
3,397.90
6,541.40
12,355.30
22,265.40
28,587.20
23,700.60
Capital Expenditures
35.70
25.40
15.40
58.70
152.00
Purchase/Sale of Investments
-
-
23,592.60
11,478.50
10,509.80
Net Investing Cash Flow
35.70
25.40
23,608.10
11,419.80
10,357.80
Issuance/Reduction of Debt, Net
1,214.80
2.40
-
-
-
Net Financing Cash Flow
5,204.10
8,357.90
43,629.50
7,092.50
20,525.00
Net Change in Cash
1,759.00
1,745.10
7,649.40
3,752.90
2,315.20
Free Cash Flow
3,433.60
6,566.80
12,370.80
22,324.10
28,739.20
Change in Capital Stock
3,989.30
1,637.00
43,603.00
7,092.50
20,525.00
Exchange Rate Effect
11.40
46.00
16.60
0.20
19.60

About CorMedix

View Profile
Address
400 Connell Drive
Berkeley Heights New Jersey 07921
United States
Employees -
Website http://www.cormedix.com
Updated 07/08/2019
CorMedix, Inc. operates as a pharmaceutical and medical device company that seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E.